The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
U.S. FDA grants Fast Track designation to DSP-5336 for the treatment of R/R AML
DSP-5336, an oral inhibitor of the menin and mixed-lineage leukemia (MLL) interaction, for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) with a KMT2A rearrangement.1
DSP-5336 is currently under investigation as part of a phase I/II study in patients with relapsed/refractory AML.1 The latest data from this study were presented at the European Hematology Association (EHA) 2024 Hybrid Congress. Data presented highlighted an objective response rate of 57%, which included responses in patients with both nucleophosmin 1 (NPM1) mutation and KMT2A (MLL) rearrangement.1 A complete remission or complete with partial hematologic recovery was observed in 24% of patients.1 There were no dose-limiting toxicities observed, nor cardiac signals or treatment-related discontinuations/deaths.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?